Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children

Pediatric Transplantation

Volumn 18, Issue 3, 2014, Pages 294-301

  Okamoto, Yasuhiro ^a   Nagatoshi, Yoshihisa ^b   Kosaka, Yoshiyuki ^c   Kikuchi, Akira ^d   Kato, Shunichi ^e   Kigasawa, Hisato ^f   Horikoshi, Yasuo ^g   Oda, Megumi ^h   Kaneda, Makoto ⁱ   Mori, Tetsuya ^j   Mugishima, Hideo ^k   Tsuchida, Masahiro ^l   Taniguchi, Shuichi ^m   Kawano, Yoshifumi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c KOBE CHILDREN S HOSPITAL   (Japan)

^d SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^e TOKAI UNIVERSITY   (Japan)

^f KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^g SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^h OKAYAMA UNIVERSITY   (Japan)

ⁱ ASAHIKAWA MEDICAL COLLEGE   (Japan)

^j NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^k NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l Ibaraki Children's Hospital   (Japan)

^m TORANOMON HOSPITAL   (Japan)

more..

Author keywords

adverse events; area under the curve; busulfan; children

Indexed keywords

BUSULFAN; MYELOABLATIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CHRONIC GRANULOMATOUS DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; FEMALE; GAS CHROMATOGRAPHY; GRAFT FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; JAPANESE; JUVENILE MYELOMONOCYTIC LEUKEMIA; LIVER VEIN OBSTRUCTION; MALE; MASS SPECTROMETRY; METACHROMATIC LEUKODYSTROPHY; MULTICENTER STUDY; OPEN STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; SEPTIC SHOCK; SOLID TUMOR; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC NEOPLASMS; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; MASS FRAGMENTOGRAPHY;

ADOLESCENT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BUSULFAN; CHILD; CHILD, PRESCHOOL; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; JAPAN; MALE; MYELOABLATIVE AGONISTS; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING;

EID: 84898479238     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12236     Document Type: Article

References (16)

1. McCune JS, Gooley T, Gibbs JP, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002: 30: 167-173.
2. Copelan EA, Bechtel TP, Avalos BR, et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 2001: 27: 1121-1124.
3. Bhagwatwar HP, Phadungpojna S, Chow DS, Andersson BS,. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol 1996: 37: 401-408.
4. Schiltmeyer B, Klingebiel T, Schwab M, et al. Population pharmacokinetics of oral busulfan in children. Cancer Chemother Pharmacol 2003: 52: 209-216.
5. Dalle JH, Wall D, Theoret Y, et al. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: Clinical and pharmacokinetic results. Bone Marrow Transplant 2003: 32: 647-651.
6. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C,. IV busulfan in pediatrics: A novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 2004: 33: 979-987.
7. Kim AH, Tse JC, Ikeda A, Moore TB,. Evaluating pharmacokinetics and pharmacodynamics of intravenous busulfan in pediatric patients receiving bone marrow transplantation. Pediatr Transplant 2009: 13: 971-976.
8. Wall DA, Chan KW, Nieder ML, et al. Pediatric Blood, Marrow Transplant Consortium. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer 2010: 54: 291-298.
9. Vassal G, Michel G, Espérou H, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008: 61: 113-123.
10. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987: 44: 778-783.
11. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED,. Venoocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 1984: 4: 116-122.
12. Vassal G, Re M, Gouyette A,. Gas chromatographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard. J Chromatogr 1988: 428: 357-361.
13. Malär R, Sjöö F, Rentsch K, Hassan M, Güngür T,. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatr Transplant 2011: 15: 580-588.
14. Gibbs JP, Murray G, Risler L, Chien JY, Dev R, Slattery JT,. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res 1997: 57: 5509-5516.
15. Michel G, Valteau-Couanet D, Gentet JC, et al. Weight-based strategy of dose administration in children using intravenous busulfan: Clinical and pharmacokinetic results. Pediatr Blood Cancer 2012: 58: 90-97.
16. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983: 309: 1347-1353.